Company Overview
Valencia Technologies is a privately held neuromodulation company specializing in innovative solutions for bladder dysfunction. The company is renowned for its product, eCoin® Therapy, designed specifically for treating Urge Urinary Incontinence (UUI). The device is a revolutionary, leadless tibial neurostimulator, known for its minimally invasive procedure, automatic stimulation capabilities, and FDA approval. Headquarters are located in Valencia, California, situating the company solidly within the medical equipment manufacturing industry.
Key Products and Innovations
Valencia Technologies' flagship product:
- eCoin® Therapy: A tibial implant effectively reducing symptoms of UUI, pivotal in Overactive Bladder (OAB) management. The eCoin® is a fully implantable neurostimulator that requires no lead wires, external remote controls, or recharging. Integrated into clinical guidelines and covered by various insurance providers, including Anthem Blue Cross and Blue Shield, it marks a significant advancement over traditional therapies.
Leadership Team
- Jeff Greiner
Position: Chairman of the Board and Founder
Background: Jeff Greiner founded Valencia Technologies, leveraging extensive experience in the med-tech industry to guide the company. His previous leadership at Advanced Bionics led to substantial growth and acquisitions.
- Russ Ramanayake
Position: Vice President of Finance
Background: With over 25 years in medical devices, Russ Ramanayake brings expertise in regulatory affairs and corporate finance, managing mergers, acquisitions, and financial operations.
- Erik Styacich
Position: Vice President of Sales
Background: Erik Styacich, with over 17 years of experience, leads sales at Valencia, focusing on Urology and Neuromodulation markets. His prior leadership roles were at Teleflex and Nuvectra Medical.
- Ann Decker
Position: Vice President of Reimbursement and Health Policy
Background: Ann Decker provides 30 years of experience in medical device reimbursement and policy strategy, enhancing coverage and reimbursement processes for Valencia's products.
- Nicole Barber
Position: Vice President of Regulatory & Clinical Affairs
Background: With 19 years in regulatory compliance and clinical affairs, Nicole Barber's leadership enhances Valencia Technologies' regulatory operations in implantable medical devices.
Recent Developments
- FDA Approval: The eCoin® device received FDA approval, marking a significant milestone.
- Commercial Expansion: Initiated the first commercial implantation of the eCoin®.
- Insurance Inclusion: Broadened insurance coverage including by entities like Anthem Blue Cross and Blue Shield.
Financials and Funding
Valencia Technologies has raised a total of $21.9 million in funding from significant investors including BMG and NIO Capital. This funding underpins ongoing innovation and market expansion strategies. The company's annual revenue stands at approximately $12 million, highlighting its competitive market presence.
Contact Information
- Headquarters: 28464 Westinghouse Place, Valencia, CA 91355, United States
- Phone: 661.775.1414
- Email: info@valenciatechnologies.com
- Website: [valenciatechnologies.com](https://valenciatechnologies.com)
Competitive Landscape
Valencia Technologies operates in a dynamic market with several key competitors:
- Key Emerging Competitors: SoranusMED, Aidee, and CeleFlux.
- Top Established Competitors: Amphora Medical, EMKinetics, Cogentix Medical, BlueWind Medical, Axonics, and Medtronic.
- Other Competitors: Aperio Technologies, Monobind, Lief Therapeutics, Remon Medical Technologies, Presidio Medical.
With an estimated annual revenue of $12 million, Valencia Technologies' position against these competitors exemplifies both the challenges and opportunities within the neuromodulation sector. Understanding this landscape is vital for stakeholders evaluating strategic initiatives and potential growth opportunities within the industry.
